T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-11-09: Form 8-K; Period of report 2021-11-05; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2021-11-05: Form 8-K; Period of report 2021-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2021-10-19: Form 8-K; Period of report 2021-10-18; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2021-10-04: Form 8-K; Period of report 2021-09-30; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-11-09 | 8-K | 2021-11-05 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On November 5, 2021, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). | d215255d8k.htm |
| 2021-11-05 | 8-K | 2021-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2021, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2021 and held a conference call to discuss those results. | d248372d8k.htm |
| 2021-10-19 | 8-K | 2021-10-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 18, 2021, the Board of Directors (the “Board”) of T2 Biosystems, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, elected Laura Adams to serve as a director of the Company. | d245949d8k.htm |
| 2021-10-04 | 8-K | 2021-09-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d237126d8k.htm |
| 2021-09-08 | 8-K | 2021-09-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d144846d8k.htm |
| 2021-08-10 | 8-K | 2021-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2021, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2021 and held a conference call to discuss those results. | d122609d8k.htm |
| 2021-07-23 | 8-K | 2021-07-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.02 On July 22, 2021, John McDonough tendered his resignation as a director of T2 Biosystems, Inc. (the “Company”), effective July 23, 2021. 5.03 On July 23, 2021, the Company held the adjourned portion of its Annual Meeting of Stockholders (the “Annual Meeting”). 5.07 At the Annual Meeting, there were a total of 148,491,673 shares of the Company’s common stock, par value $0.001 per share, outstanding and entitled to vote, as of the April 28, 2021 record date. 8.01 Based on an in silico analysis of SARS-CoV-2 sequences, we believe the T2SARS-CoV-2 assay will demonstrate the ability to detect all variants of interest, including the delta and lambda variants. | d92089d8k.htm |
| 2021-06-28 | 8-K | 2021-06-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.02 T2 Biosystems, Inc. (the “Company”) held its annual meeting of stockholders on June 25, 2021 (the “Annual Meeting”). 5.07 At the Annual Meeting, there were a total of 148,491,673 shares of the Company’s common stock, par value $0.001 per share, outstanding and entitled to vote at the Annual Meeting, as of the April 28, 2021 record date. | d138122d8k.htm |
| 2021-05-11 | 8-K | 2021-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2021, T2 Biosystems, Inc. (the “Company”) held a conference call to discuss its financial results for its fiscal quarter ended March 31, 2021. | d102306d8k.htm |
| 2021-05-06 | 8-K | 2021-04-30 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.02 On May 6, 2021, T2 Biosystems, Inc. (the “Company”) issued a press release announcing preliminary estimated financial results for its fiscal quarter ending March 31, 2021. 8.01 • Total revenue of $7.0 million, an increase of 173% compared to the prior year period. | d76694d8k.htm |
| 2021-03-09 | 8-K | 2021-03-04 | 2.02 Results of Operations and Financial Condition | 2.02 On March 4, 2021, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter and year ended December 31, 2020 and held a conference call to discuss those results. | d95678d8k.htm |
| 2021-01-27 | 8-K | 2021-01-25 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition | 1.01 Entry into a Material Definitive Agreement. 2.02 On January 26, 2021, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter and full year ended December 31, 2020. | d106954d8k.htm |